PRNewsWire
10 Aug 2026, 00:00 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Innovent Biologics and Daiichi Sankyo entered an exclusive agreement giving Innovent sole commercialization rights for Vanflyta (quizartinib) in China. — Expanding a commercial portfolio to 20 products with a targeted oncology drug provides a direct revenue growth catalyst for Innovent.
+0.60Vanflyta received approval in China in June 2026 for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). — Regulatory approval is a prerequisite for revenue generation and confirms the drug's viability in a significant patient population.
+0.40Daiichi Sankyo will retain responsibility for the development, manufacturing, and supply of Vanflyta under the agreement. — This reduces Innovent's operational risk and capital expenditure by outsourcing the supply chain to the originator.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Entered an exclusive agreement to commercialize Vanflyta in China, expanding its oncology portfolio.
Secured a commercial partner in China to accelerate patient access to its drug Vanflyta.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
5h ago
